Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin vs Heparin in Ruptured Intracranial Aneurysms (BUILD)
NCT04532333Phase 3Unknown
- Sponsor
- Changhai Hospital
- Start
- Aug 2020
- Primary completion
- May 2021
- Modality
- Peptides, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of bivalirudin in intracranial aneurysm and subarachnoid hemorrhage (SAH) (2 arms), sponsored by Changhai Hospital. Primary endpoint: Procedure-related complication at 30 days. Status: unknown.
02
Drugs
bivalirudin
03
Conditions
intracranial aneurysmsubarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT04532333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532333.